Literature DB >> 26131134

MicroRNA-222 promotes human non-small cell lung cancer H460 growth by targeting p27.

Chongjun Zhong1, Shengguang Ding1, Yiming Xu1, Haitao Huang1.   

Abstract

Two highly homologous microRNAs (miRNAs, miRs), miR-222 and miR-221, act as a cluster in cellular regulation. We have previously reported that miR-221 promoted the growth of human non-small cell lung cancer cell line H460. However, the role of miR-222 in regulating the growth of H460 is unclear. H460 cells were transfected with miR-222 mimics, inhibitors or their negative controls and their effects were confirmed by Real-time quantitative reverse transcription polymerase chain reactions (qRT-PCRs). Cell viability was assessed by Cell Counting Kit-8 (CCK-8) while cell proliferation was determined by 5-Ethynyl-2'-deoxyuridine (EdU) assay. P27 and P57, two putative targets of miR-222, were checked by qRT-PCRs. We found that miR-222 overexpression increased cell viability and proliferative rate in H460 cells while opposite effects were obtained by down-regulation of miR-222. P27 but not P57 was identified as a potential target of miR-222 in H460 cells as P27 was negatively regulated by miR-222 in the protein level. In summary, the present study indicates that miR-222 controls the growth of H460 likely by targeting P27. Inhibition of miR-222 might be a novel therapy for human non-small cell lung cancer.

Entities:  

Keywords:  MicroRNA; cell viability; human non-small cell lung cancer; proliferation

Year:  2015        PMID: 26131134      PMCID: PMC4483927     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  41 in total

1.  Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3.

Authors:  R Gan; Y Yang; X Yang; L Zhao; J Lu; Q H Meng
Journal:  Cancer Gene Ther       Date:  2014-06-13       Impact factor: 5.987

2.  Serum microRNA-499 and microRNA-208a as biomarkers of acute myocardial infarction.

Authors:  Junjie Xiao; Bo Shen; Jin Li; Dongcao Lv; Yingying Zhao; Fei Wang; Jiahong Xu
Journal:  Int J Clin Exp Med       Date:  2014-01-15

3.  MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.

Authors:  Elisa Giovannetti; Niccola Funel; Godefridus J Peters; Marco Del Chiaro; Leyla A Erozenci; Enrico Vasile; Leticia G Leon; Luca E Pollina; Annemieke Groen; Alfredo Falcone; Romano Danesi; Daniela Campani; Henk M Verheul; Ugo Boggi
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

4.  A microRNA polycistron as a potential human oncogene.

Authors:  Lin He; J Michael Thomson; Michael T Hemann; Eva Hernando-Monge; David Mu; Summer Goodson; Scott Powers; Carlos Cordon-Cardo; Scott W Lowe; Gregory J Hannon; Scott M Hammond
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

5.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

6.  miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.

Authors:  Michela Garofalo; Gianpiero Di Leva; Giulia Romano; Gerard Nuovo; Sung-Suk Suh; Apollinaire Ngankeu; Cristian Taccioli; Flavia Pichiorri; Hansjuerg Alder; Paola Secchiero; Pierluigi Gasparini; Arianna Gonelli; Stefan Costinean; Mario Acunzo; Gerolama Condorelli; Carlo Maria Croce
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

7.  The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines.

Authors:  Tong Sun; Qianben Wang; Steven Balk; Myles Brown; Gwo-Shu Mary Lee; Philip Kantoff
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

8.  Regulation of p27Kip1 by miRNA 221/222 in glioblastoma.

Authors:  Jana K Gillies; Ian A J Lorimer
Journal:  Cell Cycle       Date:  2007-05-31       Impact factor: 4.534

9.  Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.

Authors:  M H Lee; I Reynisdóttir; J Massagué
Journal:  Genes Dev       Date:  1995-03-15       Impact factor: 11.361

10.  Down-regulation of mir-221 and mir-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1.

Authors:  Xiao Yang; Yingmei Yang; Rong Gan; Lingxu Zhao; Wei Li; Huaibin Zhou; Xiaojuan Wang; Jianxin Lu; Qing H Meng
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

View more
  15 in total

1.  MicroRNA-216b regulated proliferation and invasion of non-small cell lung cancer by targeting SOX9.

Authors:  Sida Liu; Han Dong; Hui Dai; Danwei Liu; Zhihao Wang
Journal:  Oncol Lett       Date:  2018-04-25       Impact factor: 2.967

Review 2.  MicroRNA-338-3p suppresses metastasis of lung cancer cells by targeting the EMT regulator Sox4.

Authors:  Yang Li; Peirui Chen; Lingling Zu; Bin Liu; Min Wang; Qinghua Zhou
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

3.  Gastrin-induced miR-222 promotes gastric tumor development by suppressing p27kip1.

Authors:  Katie A Lloyd; Andrew R Moore; Bryony N Parsons; Adrian O'Hara; Malcolm Boyce; Graham J Dockray; Andrea Varro; D Mark Pritchard
Journal:  Oncotarget       Date:  2016-07-19

4.  MicroRNA-338-3p suppresses cell proliferation and induces apoptosis of non-small-cell lung cancer by targeting sphingosine kinase 2.

Authors:  Guowei Zhang; Hao Zheng; Guojun Zhang; Ruirui Cheng; Chunya Lu; Yijie Guo; Guoqiang Zhao
Journal:  Cancer Cell Int       Date:  2017-04-17       Impact factor: 5.722

5.  MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival.

Authors:  Xiaodan Fu; Yimin Li; Ayesha Alvero; Juanni Li; Qihui Wu; Qing Xiao; Yulong Peng; Yongbin Hu; Xiang Li; Wenguang Yan; Ke Guo; Wenjuan Zhou; Yong Wang; Junwen Liu; Yu Zhang; Gil Mor; Jifang Wen; Gang Yin
Journal:  Oncotarget       Date:  2016-12-06

6.  Overexpression of miR-758 inhibited proliferation, migration, invasion, and promoted apoptosis of non-small cell lung cancer cells by negatively regulating HMGB.

Authors:  Guo-Hua Zhou; Yi-Yu Lu; Jing-Lian Xie; Zi-Kun Gao; Xiao-Bo Wu; Wei-Shen Yao; Wei-Guang Gu
Journal:  Biosci Rep       Date:  2019-01-18       Impact factor: 3.840

Review 7.  New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies.

Authors:  Erika Larrea; Carla Sole; Lorea Manterola; Ibai Goicoechea; María Armesto; María Arestin; María M Caffarel; Angela M Araujo; María Araiz; Marta Fernandez-Mercado; Charles H Lawrie
Journal:  Int J Mol Sci       Date:  2016-04-27       Impact factor: 5.923

8.  miR-222 attenuates cisplatin-induced cell death by targeting the PPP2R2A/Akt/mTOR Axis in bladder cancer cells.

Authors:  Li-Ping Zeng; Zheng-Mao Hu; Kai Li; Kun Xia
Journal:  J Cell Mol Med       Date:  2016-01-22       Impact factor: 5.310

9.  MicroRNA-222 Controls Human Pancreatic Cancer Cell Line Capan-2 Proliferation by P57 Targeting.

Authors:  Yingying Zhao; Yuqiong Wang; Yuefeng Yang; Jingqi Liu; Yang Song; Yan Cao; Xiaoyu Chen; Wenzhuo Yang; Fei Wang; Jun Gao; Zhaoshen Li; Changqing Yang
Journal:  J Cancer       Date:  2015-10-16       Impact factor: 4.207

Review 10.  A meta-analytic review of the association between two common SNPs in miRNAs and lung cancer susceptibility.

Authors:  Sha Xiao; Songzan Sun; Wenfang Long; Shicheng Kuang; Yunru Liu; Hairong Huang; Jing Zhou; Yongjiang Zhou; Xiaobo Lu
Journal:  Onco Targets Ther       Date:  2018-04-30       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.